Avosentan

Summary

Avosentan (CHEMBL3989834) is a phase-3 clinical-stage small molecule targeting EDNRA; indicated across 1 condition including diabetic kidney disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (EDNRA)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 479.5 Da · C23H21N5O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989834
Name	Avosentan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9912992
Molecular formula	C23H21N5O5S
Molecular weight	479.5
InChIKey	YBWLTKFZAOSWSM-UHFFFAOYSA-N

SMILES: CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC

IUPAC name: N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide

Also known as: Avosentan, Ro670565, SPP-301, SPP301, AVOSENTAN

Patent coverage: 142 distinct patent families (364 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 232 (64%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
EDNRA	ETA receptor	Antagonist	7.3	0.1%	P25101

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Endothelin receptor type B, Endothelin-1 receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
EDNRA	8.85	IC50	1.4	nM	CHEMBL_ACT_19405688
EDNRA	8.51	IC50	3.1	nM	CHEMBL_ACT_19405689
EDNRB	6.22	IC50	600	nM	CHEMBL_ACT_19405666
EDNRB	5.92	IC50	1200	nM	CHEMBL_ACT_19405690

Target pathways

Aggregated over 1 target gene(s): EDNRA.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	1	EDNRA
G alpha (q) signalling events	1	EDNRA

Dominant GO biological processes

GO term	Targets
mitotic cell cycle	1
branching involved in blood vessel morphogenesis	1
response to hypoxia	1
in utero embryonic development	1
blood vessel remodeling	1
response to amphetamine	1
regulation of heart rate	1
glomerular filtration	1
cardiac chamber formation	1
left ventricular cardiac muscle tissue morphogenesis	1
atrial cardiac muscle tissue development	1
cardiac neural crest cell migration involved in outflow tract morphogenesis	1
noradrenergic neuron differentiation	1
intracellular calcium ion homeostasis	1
smooth muscle contraction	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetic kidney disease	3	MONDO:0005016	EFO:0000401

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00120328	PHASE3	TERMINATED	To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

41 molecules share ≥1 primary target. Top 41 by shared-target count:

Molecule	Source	Status	Shared targets
BOSENTAN	ChEMBL + PubChem	Phase 4 (approved)	EDNRA
SPARSENTAN	ChEMBL + PubChem	Phase 4 (approved)	EDNRA
ACYCLOVIR	ChEMBL	Phase 4 (approved)	EDNRA
AMBRISENTAN	ChEMBL	Phase 4 (approved)	EDNRA
AMIODARONE	ChEMBL	Phase 4 (approved)	EDNRA
APROCITENTAN	ChEMBL	Phase 4 (approved)	EDNRA
ENOXACIN	ChEMBL	Phase 4 (approved)	EDNRA
FLUOXETINE	ChEMBL	Phase 4 (approved)	EDNRA
GRAMICIDIN	ChEMBL	Phase 4 (approved)	EDNRA
IRBESARTAN	ChEMBL	Phase 4 (approved)	EDNRA
MACITENTAN	ChEMBL	Phase 4 (approved)	EDNRA
MELOXICAM	ChEMBL	Phase 4 (approved)	EDNRA
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	EDNRA
PIOGLITAZONE	ChEMBL	Phase 4 (approved)	EDNRA
SITAXENTAN	ChEMBL	Phase 4 (approved)	EDNRA
SULFATHIAZOLE	ChEMBL	Phase 4 (approved)	EDNRA
SULFISOXAZOLE	ChEMBL	Phase 4 (approved)	EDNRA
SUNITINIB	ChEMBL	Phase 4 (approved)	EDNRA
ATRASENTAN	ChEMBL	Phase 3	EDNRA
CLAZOSENTAN	ChEMBL	Phase 3	EDNRA
DARUSENTAN	ChEMBL	Phase 3	EDNRA
EXISULIND	ChEMBL	Phase 3	EDNRA
TEZOSENTAN	ChEMBL	Phase 3	EDNRA
ZIBOTENTAN	ChEMBL	Phase 3	EDNRA
BQ-123	ChEMBL	Phase 2	EDNRA
EDONENTAN	ChEMBL	Phase 2	EDNRA
ENDOTHELIN	ChEMBL	Phase 2	EDNRA
ENRASENTAN	ChEMBL	Phase 2	EDNRA
FANDOSENTAN	ChEMBL	Phase 2	EDNRA
FELOPRENTAN	ChEMBL	Phase 2	EDNRA
Afatinib	PubChem	Approved	EDNRA
Apixaban	PubChem	Approved	EDNRA
Binimetinib	PubChem	Approved	EDNRA
chenodiol	PubChem	Approved	EDNRA
Dihydroergotamine	PubChem	Approved	EDNRA
Fidaxomicin	PubChem	Approved	EDNRA
Fulvestrant	PubChem	Approved	EDNRA
Imipenem	PubChem	Approved	EDNRA
Propoxyphene	PubChem	Approved	EDNRA
Pyrazinamide	PubChem	Approved	EDNRA
Tafamidis	PubChem	Approved	EDNRA